<?xml version="1.0" encoding="UTF-8"?>
<p id="para220">Between March 30, 2015, and Aug 3, 2018, 79 patients were enrolled. Every patient who was eligible according to the per-protocol selection criteria and diagnosed at participating centres was enrolled. The trial was ended after accrual completion; the database lock was Dec 31, 2019. Four patients were excluded after enrolment before the start of study treatment because of unrelated laboratory abnormalities (two patients), disease only at flow cytometry examination of the cerebrospinal fluid (one), and death at the same time as registration (one). 75 patients with a median age of 58 years (IQR 50â€“66) were assessable and received the first MATRix course (
 <xref rid="fig1" ref-type="fig">figure 1</xref>), 38 (51%) of whom were male and 37 (49%) of whom were female (
 <xref rid="tbl1" ref-type="table">table 1</xref>; 
 <xref rid="sec1" ref-type="sec">appendix p 6</xref>).
</p>
